Jennifer R. Brown, MD, PhD, on CLL: Resistance to Pirtobrutinib in Pretreated Disease

July 13, 2023 By The ASCO Post Staff
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase I/II findings from the Bruin study of resistance to pirtobrutinib in patients with covalent BTK inhibitor–pretreated chronic lymphocytic leukemia (CLL). The aim of the study was to explore the genomic evolution of resistance to this agent.

Related Content